Clinical Trial Imaging Market Report 2026

The clinical trial imaging market size has grown strongly in recent years. It will grow from $1.58 billion in 2025 to $1.72 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing complexity of clinical trial protocols, growing use of imaging endpoints in oncology trials, expansion of global clinical trials, rising regulatory emphasis on imaging accuracy, availability of advanced imaging modalities.

The clinical trial imaging market size is expected to see strong growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing adoption of decentralized clinical trials, rising investments in ai-enabled imaging platforms, growing demand for real-time imaging analytics, expansion of precision medicine trials, increasing integration of imaging with clinical data platforms. Major trends in the forecast period include increasing adoption of AI-assisted image analysis, rising use of multi-modality imaging in trials, growing demand for centralized image management services, expansion of remote imaging review capabilities, enhanced focus on imaging standardization and quality control.

The increasing prevalence of chronic diseases is expected to drive the growth of the clinical trial imaging market in the coming years. Chronic diseases are long-term conditions that generally require continuous medical care and may limit daily activities or quality of life. The rising burden of chronic diseases is associated with factors such as exposure to air pollution, chemicals, and toxins, changes in lifestyle, and genetic influences. Clinical trial imaging enables effective monitoring through advanced imaging techniques, helping patients better understand their condition and the effects of treatments, which in turn improves treatment adherence and patient satisfaction. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based National Library of Medicine, the number of individuals aged 50 years and above living with at least one chronic illness is projected to increase by 99.5% by 2050, rising from 71.522 million in 2020 to 142.66 million. Therefore, the growing prevalence of chronic diseases is driving the clinical trial imaging market.

Major companies operating in the clinical trial imaging market are focusing on the development of cloud-based image viewing tools to enhance operational efficiency and improve clinical trial workflows. Cloud-based imaging tools are software platforms that use cloud computing to store, manage, and analyze medical images securely and efficiently. For example, in March 2023, Clarion, a US-based manufacturer of advanced power distribution systems, launched a cloud-based image viewer tool designed to provide real-time, on-demand access to high-resolution medical images. The tool enables near real-time, read-quality image viewing and manipulation while eliminating manual processes that were previously required. It simplifies image accessibility, ensures data security and privacy compliance, and supports full-resolution image analysis, allowing end users to derive deeper insights into clinical trial subjects.

In March 2023, Medica, a UAE-based medical company, acquired RadMD for an undisclosed amount. This acquisition represents a strategic step for Medica to enter the clinical trials market by leveraging RadMD’s expertise and industry experience. The transaction is intended to help reduce costs and improve efficiency in drug and medical device development for pharmaceutical companies, biotechnology firms, and contract research organizations. RadMD is a US-based company that specializes in providing clinical trial imaging services.

Major companies operating in the clinical trial imaging market are Koninklijke Philips N.V., Labcorp Drug Development, ICON Plc, PPD Inc., Syneos Health, Charles River Laboratories, Parexel International Corporation, Clario, Medpace Inc., Medidata Solutions Inc., Biotelemetry Inc., ProScan Imaging LLC, Invicro LLC, Perspectum, Intrinsic Imaging LLC, Datatrak Inc., IXICO Plc, Calyx Inc., Resonance Health Ltd., Anagram-ESIC SL.

North America was the largest region in the clinical trial imaging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical trial imaging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical trial imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the clinical trial imaging market by increasing costs of imported imaging hardware components, advanced scanners, data storage systems, and image analysis software used across MRI, CT, PET, and X-ray modalities. North America and Europe are most affected due to reliance on imported high-end imaging equipment, while Asia-Pacific faces higher costs for technology upgrades at research sites. These tariffs are increasing operational expenses for trial sponsors and imaging service providers and slowing equipment replacement cycles. However, they are also encouraging regional sourcing of imaging services, local software development, and greater use of cloud-based imaging platforms to optimize long-term cost structures.

The clinical trial imaging market research report is one of a series of new reports that provides clinical trial imaging market statistics, including clinical trial imaging industry global market size, regional shares, competitors with a clinical trial imaging market share, detailed clinical trial imaging market segments, market trends and opportunities, and any further data you may need to thrive in the clinical trial imaging industry. This clinical trial imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Clinical trial imaging involves the application of medical imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and X-rays to obtain detailed internal images of participants during clinical studies. These images are used to track disease progression, evaluate treatment effectiveness, and ensure patient safety. Clinical trial imaging plays a critical role in assessing the biological effects of new therapies and medical interventions.

The primary products and services in clinical trial imaging include services and software. Clinical trial imaging services encompass the use of specialized imaging techniques and standardized methodologies that support research and development activities throughout clinical trials. Key imaging modalities include computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography, and others. These imaging solutions are applied across therapeutic areas such as oncology, neurology, cardiology, endocrinology, dermatology, hematology, and others, and are distributed through direct sales and tender-based sales channels. They are utilized by end users including contract research organizations, pharmaceutical and biotechnology companies, medical device manufacturers, academic and government research institutions, and others.

The clinical trial imaging market consists of revenues earned by entities by providing services such as image protocol development, data management and integration, image processing, and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical trial imaging market also includes sales of analysis tools, clinical trial management systems, and compliance tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.